ASCO 2025 | Challenges in comparing checkpoint inhibitors in various sarcoma subtypes
Nadia Hindi, MD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, comments on the limitations of comparing immune checkpoint inhibitors in monotherapy with antiangiogenic therapy in ultra-rare sarcoma subtypes. Existing data are limited and that a randomized study is needed to provide more accurate results. Comparing results between studies is additionally challenging due to differences in patient populations and treatment histories. While there have been responses to immune checkpoint inhibitors in other studies, a pure cohort of patients treated with monotherapy is lacking, making it difficult to draw conclusions. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So that’s a tricky question because we don’t really have extensive data on immune checkpoint inhibitors in monotherapy in these histological subtypes. So our results better compare with what we know with antiangiogenic alone because in that sense we already developed a phase two study only with pazopanib in monotherapy. We have been reviewing the results of this study and comparing with the results in the Pazopanib study because indeed in the Pazopanib study the median PFS was longer...
So that’s a tricky question because we don’t really have extensive data on immune checkpoint inhibitors in monotherapy in these histological subtypes. So our results better compare with what we know with antiangiogenic alone because in that sense we already developed a phase two study only with pazopanib in monotherapy. We have been reviewing the results of this study and comparing with the results in the Pazopanib study because indeed in the Pazopanib study the median PFS was longer. But the populations are not fully comparable because in the current study 46% of the population had already been pre-treated and in fact six patients had already progressed to anti-angiogenic whereas in the other study all patients were naive to anti-angiogenic. So we don’t really know how to compare results of both studies. And to better answer this question, we should make probably a randomized study, which is quite challenging in this ultra-rare hemangioma subtype. And with regards to immunotherapy, to immune checkpoint inhibitors in monotherapy, there have been responses to immune checkpoint inhibitors described in other studies, but we don’t really have a pure cohort of patients treated with monotherapy, so it’s difficult to answer that question.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
